Tag: OTCMKTS:MDIT
SeeThruEquity Healthcare Investor Conference in S.F. to feature MEDITE Cancer Diagnostics
NEWS: MEDITE Cancer Diagnostics, Inc. (OTC:MDIT / OTCMKTS:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces today that CEO, Michaela Ott and CFO, Robert McCullough will present at the SeeThruEquity First Annual Microcap Healthcare Investor Conferfence.
MEDITE Cancer Diagnostics Reports a Profitable Q3 and Nine Month 2015 Results (OTC:MDIT)
NEWS: MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT / OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its third quarter and nine month 2015 results.
MEDITE Cancer Diagnostics Announces Mexican Distributor won Public Tender for total of 31 MEDITE Tissue Stainers
NEWS: MEDITE Cancer Diagnostics, Inc., (OTC:MDIT : OTCMKTS:MDIT) specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces its Mexican distributor, ATYDE won a public tender for delivery of 31 MEDITE tissue staining machines with a the total retail value of approximately $600,000. This is the first major sale to Mexico for MEDITE.
MEDITE Cancer Diagnostics, Inc. (OTC:MDIT) Reports Q2 and Six Month 2015 Results
ORLANDO, Fla. /eNewsChannels/ -- NEWS: MEDITE Cancer Diagnostics, Inc. ('Company,' OTCQB symbol: MDIT / OTCBB:MDIT / OTCMKTS:MDIT), specializing in the development, manufacturing, and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions announces second quarter and six month 2015 results.
